Gilead Amends Study Design

[Guest guest]

Press Release

PharmiWeb Sun, 04 Sep 2011 10:00 AM PDT

Gilead Sciences Inc. Posted on:04 Sep 11 Gilead Sciences, Inc. (Nasdaq: GILD)

today announced that, in consultation with the U.S. Food and Drug Administration

(FDA), the company will amend the design of ongoing clinical trials to

discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving

that compound in combination with pegylated interferon and ribavirin, and

another ...

Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include

GS 9190, Pegylated Interferon and ...

Business Wire Sun, 04 Sep 2011 08:08 AM PDT

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD)

today announced that, in consultation with the U.S. Food and Drug Administration

(FDA), the company will amend the design of ongoing clinical trials to

discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving

that compound in combination with pegylated interferon and ribavirin, and

another direct ...